摘要
近年来分子靶向药物已成为晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)可供选择的临床治疗方案。表皮生长因子受体(epidermal growth factor receptor,EGFR)基因突变与小分子EGFR酪氨酸激酶抑制剂(epidermal growth factor re-ceptor-tyrosine kinase inhibitor,EGFR-TKI)的临床疗效有一定相关性。然而,有些EGFR基因突变患者对EGFR-TKI的治疗并不敏感或对该类药物产生耐药。文中就EGFR基因突变与NSCLC分子靶向治疗敏感性和耐药机制的研究进展进行综述。
Molecular targeting therapy has become a new approach in the treatment of advanced non-small cell lung cancer （NSCLC）. The sensitivity of lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors （EGFR-TKIs） has been found to be associated with mutations in the tyrosine kinase domain of EGFR. However, not all mutations are sensitive to gefitinib. In this re- view, we discuss EGFR mutation and the association with sensitivity and mechanism for the acquired resistance to EGFR-TKIs.
出处
《医学研究生学报》
CAS
北大核心
2012年第12期1311-1315,共5页
Journal of Medical Postgraduates
基金
江苏省科技厅科研基金(BK2009446)
吴阶平医学基金(320.6700.09050)
关键词
表皮生长因子受体
分子靶向治疗
肺癌
基因突变
Epidermal growth factor receptor
Molecular targeted therapy
Lung cancer
Gene mutation
